🧠 New Drug Therapy Gives Hope for Alzheimer’s Prevention
A promising new treatment could one day help prevent Alzheimer’s disease. Researchers at the Lewis Katz School of Medicine at Temple University have discovered that a class of medications known as pharmacological chaperones may stop the progression of Alzheimer’s in its earliest stages. Their findings give new hope to millions of families affected by this devastating disease.
How Alzheimer’s Disease Affects the Brain
Alzheimer’s is a chronic neurodegenerative disease that gradually destroys memory, reasoning, and daily functioning. It occurs when abnormal protein deposits—known as amyloid-beta plaques and tau tangles—form in the brain. These sticky clumps disrupt the vital communication between neurons and eventually cause brain cells to die.
A simple way to visualize the disease is to imagine a ball of tangled tape. Misfolded proteins clump together, block the cell’s recycling process, and trap toxic materials inside. Over time, this buildup slows and damages the brain’s natural repair system.
What Is Pharmacological Chaperone Therapy?
To combat this, scientists have developed pharmacological chaperones—tiny molecules that help cells identify, stabilize, and recycle misfolded proteins before they cause damage. According to Temple University’s study published in Molecular Neurodegeneration, these drugs may help prevent Alzheimer’s by restoring normal brain function in mice genetically predisposed to develop the disease.
The therapy works by restoring levels of a key sorting protein called VPS35, which acts like the cell’s recycling center. VPS35 helps clear the brain of harmful proteins such as amyloid-beta and tau. In people with Alzheimer’s, VPS35 levels are much lower, leading to toxic buildup and memory loss. By boosting VPS35, pharmacological chaperones may keep neurons functioning and reduce brain damage.
Encouraging Study Results
Temple researchers tested the new therapy on young mice engineered to develop Alzheimer’s disease as they aged. The results were remarkable:
- Treated mice maintained normal memory and learning abilities.
- They had fewer tau tangles and amyloid plaques.
- VPS35 levels were restored to healthy levels.
- Neuron connections (synapses) remained intact and fully functional.
These findings suggest pharmacological chaperones could provide a safe and affordable way to prevent Alzheimer’s or slow its progression.
A Safer and More Affordable Option
“Compared to other Alzheimer’s treatments, pharmacological chaperones are inexpensive and already approved for other conditions,” explained Dr. Domenico Praticò, the study’s lead author. “They don’t block an enzyme or receptor, which means fewer side effects. Instead, they target a natural cellular process.”
The next step for Temple’s research team will be testing the drug on older mice showing Alzheimer’s symptoms. If successful, the therapy could move to human clinical trials and represent a major step forward in Alzheimer’s prevention.
Why This Research Matters
More than 6 million Americans live with Alzheimer’s disease, and that number is expected to nearly double by 2050. Finding affordable and effective prevention strategies could transform the future for patients, families, and caregivers—and reduce the growing economic burden of long-term Alzheimer’s care.
Planning Ahead for Loved Ones with Alzheimer’s
While scientists work toward a cure, it’s important for families to plan ahead. Legal and financial planning can protect your loved one’s savings, home, and future care options.
At Aging in Maine, we help families affected by Alzheimer’s and dementia develop comprehensive estate plans and long-term care strategies that protect both assets and quality of life.
📞 Call us at (207) 848-5600 to learn how we can help your family plan with confidence and peace of mind.
